FAsTEST
•Download as PPT, PDF•
0 likes•262 views
FAsTEST has devised a new method for analysis of fatty acids (including Omega3), which allows reducing the time and cost compared to other Fatty Acid analysis.
Recommended
More Related Content
What's hot
What's hot (20)
Viewers also liked
Viewers also liked (9)
Similar to FAsTEST
Similar to FAsTEST (20)
More from Davide Cilano
More from Davide Cilano (7)
Recently uploaded
Recently uploaded (20)
FAsTEST
- 1. # 1 “ Laboratory for Fatty Acid analysis “ Fatty Acid ♥ www.fastest.it
- 2. # 21. Company 2. Products 3. Market 4. Partners 5. Competition 6. Barriers 7. Team 8. Financial 9. Summary FAsTEST has devised a new method for analysis of fatty acids (including Omega3), which allows reducing the time and cost compared to other FA analysis. Customers are Medical brokers, Laboratories, Pharma and Wellness Companies Company highlightsCompany highlights
- 3. # 31. Company 2. Products 3. Market 4. Partners 5. Competition 6. Barriers 7. Team 8. Financial 9. Summary Products & services overviewProducts & services overview Fatty Acid Test in the blood Studies and research for companies / entities Partnership ProductsServices ProductsServices The activities do not have environmental impacts. Use of non-toxic gas. Limited energy ♥
- 4. # 41. Company 2. Products 3. Market 4. Partners 5. Competition 6. Barriers 7. Team 8. Financial 9. Summary Market overview and market entryMarket overview and market entry Studies Fatty Acid Test Collaboration Contracts • Research Institutions and Companies interested in studies with the aim of aligning products to customer needs • Medical-Scientific Brokers such as pharmacies, health centers, health care facilities, laboratories, medical specialists who are interested in the performance and applications in care prevention. • Company Py-Intensive where it is essential physical and mental readiness for the conduct of business. Examples are sports clubs in general, activities with high responsibilities like public transport, airlines, military. Research Institutions and Companies Brokers Medical-Scientific Company Py-Intensive Population: World 6.790 mln Europe EU 495 mln United States 307 mln Italy 58 mln Benelux 28 mln Poland 38 mln (July 2009 est.) Source CIA World Factbook 65 mln people TARGET 1.200 Research Institutions and Companies 50.000 Brokers and Practitioners 500 Py-Intensive Companies
- 5. # 51. Company 2. Products 3. Market 4. Partners 5. Competition 6. Barriers 7. Team 8. Financial 9. Summary Partners and collaboratorsPartners and collaborators Addresses Headquarters - Viale Tunisia, 38 - 20124 Milano Funding Received 2006 Winner of Match Compteneze 2007 Imprese Creative 2009 Bank Financing 2009 Startup at Parco tecnologico Padano – Lodi 2009 Selected for “Italian Business Angels - Early Stage” Some Studies... Study about the effects of moderate amounts of dairy products with Omega3 Study of different oils and their use in the preparation of bakery Effects of their horse meat on circulating levels of omega 3 fatty acids in healthy individuals Levels of Omega 3 in the blood and neurodegenerative diseases Omega 3 and PND Levels of DHA during pregnancy Profiles in AG in malnourished child population in Cambodia Effects of supplementation with DHA in children with cystic fibrosis Effects of cigarette smoking during pregnancy Fatty acids as indicators of risk of stroke and cardiovascular disease Dental disorders and fatty acids AG in the elderly population in relation to Alzheimer's... Partners Under finalisation a commercial agreement for benelux territories We are looking for partners interested in money, competence and relations with target customers
- 6. # 61. Company 2. Products 3. Market 4. Partners 5. Competition 6. Barriers 7. Team 8. Financial 9. Summary CompetitionCompetition Competition and Competitive Advantage Competitors: Italy and abroad small companies doing analysis of the AG with different methodologies Lower prices methodologies are not rigorous Higher prices are not justified FASTEST is a reference for many competitors Entrants To reach customers there are high barriers to entry to the sales channels The execution of studies require scientific accreditation that is the result of years of work Suppliers Equipment and Supplies do not have critical supply Synergies Foods and supplements with Omega3
- 7. # 71. Company 2. Products 3. Market 4. Partners 5. Competition 6. Barriers 7. Team 8. Financial 9. Summary Barriers to entryBarriers to entry Food-FunctionalFood FAsTEST: Competence in Fatty Acids Analysis + Network for Healthcare promotion and disease prevention = Fatty Acid analysis for driving food balance for Wellness Scientific Findings Prevention Wellness Prevention Wellness Needs
- 8. # 81. Company 2. Products 3. Market 4. Partners 5. Competition 6. Barriers 7. Team 8. Financial 9. Summary Management teamManagement team Claudio Galli – Partner – Scientific Management, R & D Laboratory Manager Degree in Medicine and Surgery, Professor at the Faculty of Pharmacy, Univ Milan. He has published over 200 scientific articles. In the past, President of the International Society for the Study of Fatty Acids and Lipids (ISSFAL), Director of the Center for Pharmacoeconomics, Director of School of Toxicology. Franca Marangoni - Director and Partner – Marketing, Sales Degree in Chemistry and Technology Pharmacology - PhD. Doctor of research in food toxicology. Scientific coordinator N.F.I. (Nutrition Fundation International). Franca has performed studies for Danone, Novartis, Parmalat on innovative food products with Omega3. Davide Cilano – Director and Partner – Administration, Finance, Information Technology Degree in Computer Science with MBA and experience in project management and Business process reingeneering in many industry sectors (Finance, Multimedia, Consumer goods, Pharma).
- 9. # 91. Company 2. Products 3. Market 4. Partners 5. Competition 6. Barriers 7. Team 8. Financial 9. Summary Financial projections and Investment opportunityFinancial projections and Investment opportunity Belgium, Netherlands, Luxembourg, Poland BEP FAsTEST Commission 30% I° Profit m. 45% II° Profit m.25% Public Institutions and Companies. People I° Profit m. 75% II ° Profit m.25% Company Py-Intensive Brokers Medical-Scientific Financials Removed on Public version
- 10. # 101. Company 2. Products 3. Market 4. Partners 5. Competition 6. Barriers 7. Team 8. Financial 9. Summary Use of funds and Exit strategyUse of funds and Exit strategy Financials Removed on Public version
- 11. # 111. Company 2. Products 3. Market 4. Partners 5. Competition 6. Barriers 7. Team 8. Financial 9. Summary Resources needed beyond capitalResources needed beyond capital ♥ www.fastest.it “ Laboratory for Fatty Acid analysis and research “ Needs: Partnership for products and services promotion and Marketing plan competences
Editor's Notes
- Give a clear and succinct explanation of what your product/service is and does; address the problem & solution provided by your company. You should include graphics, screen grabs, photographs, etc. Explain why your product/service is attractive to targeted customers. What is the customer benefit?
- Present your company name and logo, your name and professional title, and your contact information. You should include a visual of your product/service in the background during your introduction to stimulate interest.
- Identify market size and prospective growth. Describe any market trends. Identify your product’s positioning within the market. Outline your market entry strategy and sales strategy. Describe your sales and marketing plan (briefly). If applicable, explain business model (e.g., how you make money). Describe your product development plan and benchmarks you intend to achieve over time. The Importance of Prevention for containment of public spending Italian Health Spending Per Capita 2006 1700 € 1300€ in 2003 - ISTAT-2009 Benelux Spending Per Capita 2006 3000€ 2200€ in 2003 - WHO - World Health Organisation-2009
- Identify existing and potential strategic partners and prospective pilot or test sites (or initial customers whether or not they generate revenue) for your products or services. Describe why they would partner with you and how the partnership would be a win-win relationship for you both.
- Provide a matrix to identify prospective competitors and show how you are differentiated from those competitors. Distinguish their offering as inferior to your Company’s products/services and identify differing market approaches, business strategies, resources, etc.
- What have you done to keep your competitors from entering the market and successfully competing against you? This includes intellectual property, patents, trademarks, first-to-market, other company assets, etc.
- Introduce the company founders and key employees. Give brief biographies regarding their backgrounds in the relevant industries and in business/technologies if applicable. How is the team uniquely qualified to build this particular business or project into a successful enterprise?
- Describe the company’s annual revenue projections over the next five years. When will the company cross over into profitability? What are the expected profit margins? (This should all be on one easy to read graph) Describe how much money is being raised and the type of securities offered. Give Company’s pre-money valuation.
- How will the money invested be spent? (In euros and percentages) What allocations go to sales and marketing, research and development, etc. (This should be on an easy to read pie chart) Explain how and when the investors will get their investment back. Identify the estimated returns on investment over what period of time. Will the company be acquired? Will it go on the public markets via an initial public offering? Explain how and why the company’s business will ramp up and provide a return to investors.
- Describe the resources beyond capital needed by your company (e.g., customer introductions, employee and partner referrals, etc.) Include your contact information and company logo once again. Include testimonials from customers or potential customers. This is your final slide and you will leave this slide up during the transition into the Q&A session.